{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-25-000093","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2025-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.130118+00:00","generated_at":"2026-05-19T01:49:36.784090+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Centessa shareholders approve all proposals at 2025 AGM, including director re-elections","bullets":["Re-elected Arjun Goyal with 116.9M votes for, 463,793 against; Samarth Kulkarni with 97.7M for, 19.6M against.","Approved KPMG LLP as UK statutory auditors and KPMG LLP (Delaware) as independent auditor for FY2025.","Adopted UK statutory accounts for FY2024; no dividend recommended.","Authorized directors to allot shares up to £133,184 nominal value under Companies Act.","Special resolution passed to empower board to allot equity for cash without pre-emption rights."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-25-000093","json":"https://secwatch.observer/filing/0001847903-25-000093.json","markdown":"https://secwatch.observer/filing/0001847903-25-000093.md","text":"https://secwatch.observer/filing/0001847903-25-000093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790325000093/0001847903-25-000093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790325000093/cnta-20250620.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T01:49:36.784090+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}